SABR in oligometastatic breast cancer: Current status and future directions

Oligometastatic breast cancer (OMBC) is a heterogeneous disease with intrinsic biological diversity. It is increasingly accepted in clinical practice that patients with OMBC could be treated with the expectation of long-term disease remission. Local ablative treatments, such as radiotherapy or surge...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rachel Stewart, Michelle White, Jennifer Tan, Shankar Siva, Lama Karroum, Steven David
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Breast cancer Oligometastatic Radiotherapy Surgery Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/fef5ad287b3d47d186dc6b1a21098ab2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fef5ad287b3d47d186dc6b1a21098ab2
record_format	dspace
spelling	oai:doaj.org-article:fef5ad287b3d47d186dc6b1a21098ab22021-11-04T04:26:22ZSABR in oligometastatic breast cancer: Current status and future directions1532-308010.1016/j.breast.2021.10.009https://doaj.org/article/fef5ad287b3d47d186dc6b1a21098ab22021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0960977621009796https://doaj.org/toc/1532-3080Oligometastatic breast cancer (OMBC) is a heterogeneous disease with intrinsic biological diversity. It is increasingly accepted in clinical practice that patients with OMBC could be treated with the expectation of long-term disease remission. Local ablative treatments, such as radiotherapy or surgery have a role in this setting. At present, patients that may benefit are characterised by low tumour burden, long disease-free interval and the capacity to completely ablate all sites of disease. In the future, biological or genomic classifiers may help predict which patients may benefit the most from local ablative treatments. This review provides an overview of the proposed classifications of oligometastatic disease and outlines the standard systemic treatment options of endocrine therapy, chemotherapy, and immunotherapy. The evidence for localized treatment with stereotactic ablative body radiotherapy (SABR) is presented. We discuss current active trials in oligometastatic cancer and discuss potential future directions for the use of SABR in the treatment of OMBC.Rachel StewartMichelle WhiteJennifer TanShankar SivaLama KarroumSteven DavidElsevierarticleBreast cancerOligometastaticRadiotherapySurgeryNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast, Vol 60, Iss , Pp 223-229 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Breast cancer Oligometastatic Radiotherapy Surgery Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Breast cancer Oligometastatic Radiotherapy Surgery Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Rachel Stewart Michelle White Jennifer Tan Shankar Siva Lama Karroum Steven David SABR in oligometastatic breast cancer: Current status and future directions
description	Oligometastatic breast cancer (OMBC) is a heterogeneous disease with intrinsic biological diversity. It is increasingly accepted in clinical practice that patients with OMBC could be treated with the expectation of long-term disease remission. Local ablative treatments, such as radiotherapy or surgery have a role in this setting. At present, patients that may benefit are characterised by low tumour burden, long disease-free interval and the capacity to completely ablate all sites of disease. In the future, biological or genomic classifiers may help predict which patients may benefit the most from local ablative treatments. This review provides an overview of the proposed classifications of oligometastatic disease and outlines the standard systemic treatment options of endocrine therapy, chemotherapy, and immunotherapy. The evidence for localized treatment with stereotactic ablative body radiotherapy (SABR) is presented. We discuss current active trials in oligometastatic cancer and discuss potential future directions for the use of SABR in the treatment of OMBC.
format	article
author	Rachel Stewart Michelle White Jennifer Tan Shankar Siva Lama Karroum Steven David
author_facet	Rachel Stewart Michelle White Jennifer Tan Shankar Siva Lama Karroum Steven David
author_sort	Rachel Stewart
title	SABR in oligometastatic breast cancer: Current status and future directions
title_short	SABR in oligometastatic breast cancer: Current status and future directions
title_full	SABR in oligometastatic breast cancer: Current status and future directions
title_fullStr	SABR in oligometastatic breast cancer: Current status and future directions
title_full_unstemmed	SABR in oligometastatic breast cancer: Current status and future directions
title_sort	sabr in oligometastatic breast cancer: current status and future directions
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/fef5ad287b3d47d186dc6b1a21098ab2
work_keys_str_mv	AT rachelstewart sabrinoligometastaticbreastcancercurrentstatusandfuturedirections AT michellewhite sabrinoligometastaticbreastcancercurrentstatusandfuturedirections AT jennifertan sabrinoligometastaticbreastcancercurrentstatusandfuturedirections AT shankarsiva sabrinoligometastaticbreastcancercurrentstatusandfuturedirections AT lamakarroum sabrinoligometastaticbreastcancercurrentstatusandfuturedirections AT stevendavid sabrinoligometastaticbreastcancercurrentstatusandfuturedirections
_version_	1718445310780375040

SABR in oligometastatic breast cancer: Current status and future directions

Ejemplares similares